Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Tivic Health Systems, Inc. (NASDAQ: TIVC) is a pioneering health technology company dedicated to transforming bioelectronic medicine. Our core mission is to develop and commercialize non-invasive products that activate the body’s natural healing mechanisms. Headquartered in San Francisco, Tivic Health is at the forefront of delivering innovative solutions for therapeutic benefit, predominantly focusing on sinus pain relief.
Our flagship product, ClearUP Sinus Relief, is a patented handheld device designed to alleviate sinus pain and congestion using ultra-low electrical currents. This device offers a natural alternative to conventional treatments like nasal sprays, pills, and saline flushes, and is particularly beneficial for individuals suffering from nasal allergies, sinus infections, chronic sinusitis, and the common cold.
Our latest innovation, Synus, provides temporary relief from sinus pain and pressure through microcurrents. This product represents our commitment to offering non-pharmaceutical options to those seeking effective and convenient sinus pain management.
With an emphasis on safety and efficacy, Tivic Health is not only advancing bioelectronic medicine but also setting new standards in patient care. Our team of dedicated professionals continually explores the therapeutic potential of microcurrents, aiming to expand our product line to treat various medical conditions in the future. We are committed to enhancing the quality of life for our users by providing accessible and effective health solutions.
For the latest updates and developments, stay tuned to our Latest News section and follow our progress as we continue to innovate and grow in the exciting field of bioelectronic medicine.
Tivic Health (Nasdaq: TIVC) released its annual CEO letter highlighting key developments in 2024 and outlook for 2025. The company improved its commercial business with ClearUP 2.0 launch, achieving 4.4-star customer reviews and establishing >65% gross margins in direct-to-consumer channels, up from 28% in 2023.
The company is focusing on Vagus Nerve Stimulation (VNS), with their non-invasive cervical approach (ncVNS) showing promising results in pilot studies with Feinstein Institute. The VNS market is forecasted to reach $21B in five years with 10.6% CAGR. Tivic has identified >$30B market opportunities for their ncVNS approach and holds 16 issued patents and 10 pending patents across multiple countries.
For 2025, Tivic plans to advance disease-specific clinical trials, improve ClearUP business cash flow, and work towards regaining Nasdaq compliance.
Tivic Health Systems (Nasdaq: TIVC) reported Q3 2024 financial results, highlighting progress in three strategic areas. The company completed a supply chain redesign for its ClearUP product line, achieving 70% gross margins. Revenue was $126,000 for Q3 and $600,000 for nine months, down 27% from 2023. The company reported a Q3 net loss of $1.4 million, improved from $1.8 million in 2023.
Tivic advanced its non-invasive vagus nerve stimulation (VNS) development, completing Phase 1a optimization study enrollment. The company partnered with Fletcher Spaght to accelerate commercial strategy and appointed Lisa Wolf as interim CFO. Cash position stood at $2.2 million, with additional $775,000 raised through stock sales in October-November 2024.
Tivic Health Systems (Nasdaq: TIVC) has completed enrollment in its optimization study for a non-invasive vagus nerve stimulation (VNS) device at The Feinstein Institute of Bioelectronic Medicine. The study aims to identify optimal device parameters affecting autonomic nervous system function. Expected completion is in early Q1 2025. The global VNS market is projected to grow from $8.59 billion in 2021 to $21.3 billion in 2030, with peripheral nerve stimulation segment growing at 35% CAGR. The company has engaged Fletcher Spaght Inc. to accelerate product development and commercial strategy following successful Phase 1 trial results.
Tivic Health Systems (Nasdaq: TIVC) has validated two European Patent Office patents in Great Britain, Germany, and France. The patents cover methods for identifying treatment points and dynamically personalizing stimulation in their sinus treatment device, ClearUP. EP3615133 protects device methods for identifying treatment points and triggering treatment modes, while EP3615134 covers methods for dynamically adjusting stimulation voltage during treatment. These validations are part of Tivic's international portfolio of 16 issued and 10 pending patents across the U.S., Europe, India, and China.
Tivic Health Systems (Nasdaq: TIVC), a bioelectronic medicine health tech company, has announced it will release its third quarter 2024 financial results on Thursday, November 14 after market close. The company will host a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders and interested parties can participate via phone or webcast, with questions to be submitted to ir@tivichealth.com by November 11.
Tivic Health Systems (Nasdaq: TIVC) has enrolled its first subject in an optimization study for their non-invasive vagus nerve stimulation device. The study, conducted by The Feinstein Institute of Bioelectronic Medicine, aims to identify optimal device parameters for influencing autonomic nervous system function. Enrollment is expected to complete by early December.
The global vagus nerve stimulation market is projected to grow from $8.59 billion in 2021 to $21.3 billion in 2030, with a 10.6% CAGR. The peripheral nerve stimulation segment, Tivic's target market, is forecast to grow at 35% CAGR. The company has partnered with Fletcher Spaght Inc. to accelerate product development and commercial strategy based on their successful Phase 1 trial results.
Tivic Health Systems (Nasdaq: TIVC) announced CEO Jennifer Ernst will present at BioFuture 2024 in New York, October 28-30. The presentation, scheduled for October 29 at 2:30 p.m. EDT, will showcase the company's advancements in bioelectronic medicine and recent data on vagus nerve stimulation.
The conference features prominent speakers including Dr. Kevin Tracey from The Feinstein Institutes for Medical Research, Tivic's clinical partners. The event will explore how vagus nerve stimulation is transforming treatments for conditions like rheumatoid arthritis, Crohn's disease, cancer, diabetes, and mental health. One-on-one meetings with investors are available through the BioFuture Showcase Partnering Platform, with a virtual component following November 5-7.
Tivic Health Systems, Inc. (Nasdaq: TIVC) has received approval from The Feinstein Institutes' Institutional Review Board for its non-invasive cervical vagus nerve stimulation (ncVNS) optimization study. This clinical research collaboration aims to refine and optimize stimulation parameters for Tivic Health's ncVNS technology. The study will use physiological measurements to enhance device performance and refine specifications such as electrode positioning and electrical waveform parameters.
Key goals include optimizing treatment strategies and accelerating product development. The study, led by Dr. Theodoros Zanos and Dr. Blake Gurfein, will inform the selection of clinical populations and shape future trial designs. Tivic Health is taking an integrated approach to clinical, product development, and go-to-market planning for its medical-grade non-invasive VNS program, aiming to generate significant new revenue.
Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, has appointed Lisa Wolf as Interim Chief Financial Officer, effective October 1, 2024. Wolf, with 30 years of financial leadership experience, replaces Kimberly Bambach, who will continue as an advisor for strategic transactions and special projects. Wolf has been a senior member of Tivic's finance team for over two years and has contributed to streamlining the company's financial operations. CEO Jennifer Ernst expressed confidence in Wolf's ability to lead Tivic into its next growth phase in bioelectronic therapeutics. The transition aims to maintain continuity while leveraging Wolf's extensive experience in public and private companies across multiple industries.
Tivic Health Systems (NASDAQ: TIVC) reported Q2 2024 financial results and growth strategies focused on vagus nerve stimulation (VNS). Key highlights include:
Financial Performance:
- Q2 2024 revenue: $140,000 (12% decrease YoY)
- H1 2024 revenue: $474,000
- H1 2024 gross margin: 42% (up from 32% in 2023)
- Q2 2024 net loss: $1.3 million (improved from $2.1 million in Q2 2023)
- H1 2024 net loss: $2.7 million ($1.5 million lower than H1 2023)
Business Updates:
- Successful Phase 1 trial of non-invasive VNS approach
- Partnership with Feinstein Institute for VNS optimization
- Launch of ClearUP 2.0
- Exclusive distribution agreement with a top medical equipment distributor
- Cost reduction initiatives, including new manufacturing and logistics arrangements
FAQ
What is the current stock price of Tivic Health Systems (TIVC)?
What is the market cap of Tivic Health Systems (TIVC)?
What is Tivic Health Systems, Inc.?
What does Tivic Health specialize in?
What is the ClearUP Sinus Relief device?
How does Tivic Health's technology work?
What conditions does ClearUP Sinus Relief treat?
What is Synus?
How is Tivic Health different from pharmaceutical companies?
Where can I learn more about Tivic Health's products?
Why choose Tivic Health products?
What are the future plans for Tivic Health?
